Pre-made Aprutumab Ixadotin benchmark antibody (Whole mAb ADC, anti-FGFR2 therapeutic antibody, Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-737

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-737 Category Tag

Product Details

Pre-made Aprutumab Ixadotin benchmark antibody (Whole mAb ADC, anti-FGFR2 therapeutic antibody, Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Aprutumab Ixadotin Biosimilar, Whole Mab Adc, Anti-Fgfr2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody Drug Conjugate

INN Name

aprutumab ixadotin

Target

FGFR2

Format

Whole mAb ADC

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1 – lambda

VD LC

IgG1 – lambda

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Bayer?HealthCare Pharmaceuticals (Leverkusen Germany)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

FGFR2

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide